Clinical Trial Update: LTX-315 and Adoptive T-cell Therapy in Advanced Soft Tissue Sarcoma (ATLAS-IT-04) [Phase 2]

View source ↗

Summary

Phase 2 trial ATLAS-IT-04 evaluating LTX-315 in combination with adoptive T-cell therapy for advanced soft tissue sarcoma has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• Adoptive T Cell Therapy
• LTX-315 (LTX-315 peptide)

Snippet

Sponsor: Lytix Biopharma AS | Conditions: Soft Tissue Sarcoma | Phase 2 | Status: COMPLETED | Results posted: 2023-11-08